Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-004831
Filing Date
2024-07-15
Accepted
2024-07-15 10:58:24
Documents
41
Period of Report
2024-05-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cnbx_i10q053124.htm   iXBRL 10-Q 428217
2 CERTIFICATION cnbx_ex3101.htm EX-31.1 10146
3 CERTIFICATION cnbx_ex3102.htm EX-31.2 10312
4 CERTIFICATION cnbx_ex3201.htm EX-32.1 5232
5 CERTIFICATION cnbx_ex3202.htm EX-32.2 4841
  Complete submission text file 0001683168-24-004831.txt   2123621

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20240531.xsd EX-101.SCH 17752
7 XBRL CALCULATION FILE cnbx-20240531_cal.xml EX-101.CAL 27526
8 XBRL DEFINITION FILE cnbx-20240531_def.xml EX-101.DEF 38970
9 XBRL LABEL FILE cnbx-20240531_lab.xml EX-101.LAB 181673
10 XBRL PRESENTATION FILE cnbx-20240531_pre.xml EX-101.PRE 142376
43 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q053124_htm.xml XML 162154
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

EIN.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 241116159
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)